Yahoo Web Search

Search results

  1. People also ask

  2. Hugh Auchincloss, Jr. (pronounced: aa-kuhn-klaas; born March 15, 1949) is an American immunologist and physician serving as the acting director of the National Institute of Allergy and Infectious Diseases since 2023. He previously served as the principal deputy director between 2006 and 2022.

    • 3, including Jake
  3. Nov 28, 2022 · Dr. Hugh Auchincloss. November 28, 2022. This is an oral history with Dr. Hugh Auchincloss, Jr., on November 28, 2022, about his career at the National Institute of Allergy and Infectious Diseases (NIAID). The interview is being done over Zoom, and the interviewer is Dr. Victoria Harden, Founding Director, Emerita, of the Office of NIH History ...

  4. Auchincloss is associate professor of surgery at Harvard Medical School and associate visiting surgeon at Massachusetts General Hospital, as well as chair of the FDA's Subcommittee on Xeno ...

  5. Feb 11, 2023 · Auchincloss, 73, a respected transplant surgeon and medical researcher, served for more than 16 years as Fauci’s low-key right-hand man at NIAID, a post he took after a long career at...

  6. Sep 15, 2023 · With each new universal influenza vaccine candidate and clinical trial, we take another step closer to that goal,” said Acting NIAID Director Hugh Auchincloss, M.D. The vaccine candidate under investigation, FluMos-v2, was designed by researchers at NIAID’s Vaccine Research Center (VRC).

  7. Sep 22, 2023 · “The evidence is clear that immune modulation can be beneficial for severely ill COVID-19 patients,” said NIAID Acting Director Hugh Auchincloss, M.D. “Patients with milder cases of COVID-19 are often administered one immune modulator, and a second treatment is added only if the patient becomes severely ill.

  8. Oct 17, 2023 · National Institute of Allergy and Infectious Diseases. Content last reviewed on October 17, 2023. Dr. Hugh Auchincloss, NIAID Principal Deputy Director, welcomes the NIAID DP2 New Innovator awardees and is proud to support these exceptional early-career investigators in their movement into independent positions.

  1. People also search for